Industry Briefs: Jan. 30, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Jan. 30, 2012
A roundup of other company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Aptar Pharma has opened a new manufacturing site near Mumbai, India. Read More

FDA has approved Pfizer’s Inlyta (axitinib), a kinase inhibitor for treating advanced renal cell carcinoma. Read More

FDA has approved Roche’s Erivedge (vismodegib) capsule for treating advanced basal cell carcinoma. Read More

Lpath has temporarily suspended dosing of iSONEP, for treating age-related macular degeneration, in clinical trials due to cGMP compliance issues at the contract fill–finish source. Read More

Roche has formally issued an offer to acquire all outstanding shares of Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion. Read More

Royal DSM and Indoco Remedies have formed a commercialization agreement for eight APIs. Read More

Valeant Pharmaceuticals has withdrawn its offer to acquire ISTA Pharmaceuticals for $7.50 per share in cash. Read More

Watson Pharmaceuticals announced plans to establish a New Jersey-based R&D technology center to support generic-drug pharmaceutical product development. Read More

People News

GlaxoSmithKline has announced changes to its board of directors. Read More

Octagon Research Solutions has appointed Gina L. Schmidt to manage the company’s global regulatory services division. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
43%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here